scholarly journals Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

2018 ◽  
Vol 93 (5) ◽  
pp. 607-614 ◽  
Author(s):  
Carlo Gambacorti-Passerini ◽  
Sergey Orlov ◽  
Li Zhang ◽  
Fadi Braiteh ◽  
Huiqiang Huang ◽  
...  
Keyword(s):  
Long Term Effects ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase 1B ◽  
Alk Positive

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

2017 ◽  
Vol 1 ◽  
pp. s95 ◽  
Author(s):  
Dee Anna Glaser ◽  
Adelaide A Hebert ◽  
Alexander Nast ◽  
William P Werschler ◽  
Stephen Shideler ◽  
...  
Keyword(s):  
Axillary Hyperhidrosis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

Abstract Not AvailableDisclosure: Study supported by Dermira.

Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study

2005 ◽  
Vol 19 (4) ◽  
pp. 392-394 ◽  
Author(s):  
Donatella Marazziti ◽  
Chiara Pfanner ◽  
Bernardo Dell’osso ◽  
Antonio Ciapparelli ◽  
Silvio Presta ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Obsessive Compulsive ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Compulsive Disorder ◽  
Augmentation Strategy

Fluvoxamine in the Treatment of Trichotillomania: An 8-Week, Open-Label Study

CNS Spectrums ◽  
1998 ◽  
Vol 3 (9) ◽  
pp. 64-71 ◽  
Author(s):  
Gary A. Christenson ◽  
Scott J. Crow ◽  
James E. Mitchell ◽  
Thomas B. Mackenzie ◽  
Ross D. Crosby ◽  
...  
Keyword(s):  
Treatment Response ◽  
Term Treatment ◽  
Hair Pulling ◽  
Short Term ◽  
Open Label ◽  
Short Term Treatment ◽  
Open Label Study ◽  
Label Study ◽  
Long Term Treatment

AbstractThis short-term, open-label study investigates short- and long-term effects of the selective serotonin reuptake inhibitor (SSRI) fluvoxamine for the treatment of trichotillomania (TTM). Additionally, this study aimed to test the hypothesis that the presence of hair pulling compulsiveness is predictive of SSRI response. Nineteen subjects meeting the Diagnostic and Statistical Manual of Mental Disorders, Third Edition Revised, (DSM-III-R) criteria for TTM were treated with fluvoxamine at doses up to 300 mg/day. Random regression analysis of change across time for patients who completed the study (n=14) and those who dropped out (n=5) revealed statistically significant improvements in Physician Rating Scale, hair-pulling episodes, Trichotillomania Impairment Scale, and Trichotillomania Symptom Severity Scale, but not in estimated amount of hair pulled. In addition, the percentage of patients' focused or compulsive hair-pulling symptoms was predictive of treatment response. Unfortunately, all three subjects who entered long-term treatment displayed substantial movement back toward baseline by the end of 6 months. We concluded that fluvoxamine produces moderate reductions in symptoms during the short-term treatment of TTM and that the presence of focused or compulsive hair pulling may be predictive of treatment response. However, responses may be short lived when treatment is extended.

Sign in / Sign up

Export Citation Format

Share Document